Addex Therapeutics(ADXN) - 2021 Q4 - Annual Report

EXHIBIT 99.1 Addex Reports Full Year 2021 Financial Results and Provides Corporate Update CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021 Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022 Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson's disease expected to report data in H1 2023 Janssen led ADX71149 Phase 2 study in epilepsy on track to report data in Q3 2022 Indivior GABAB PAM strategic collaboration extended with$4M additional ...